Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 1Phase 2 1

Status

Completed 4Active not recruiting 4Recruiting 3Not yet recruiting 2Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Genitourinary 1

Conditions

Breast Neoplasms 3Prostatic Neoplasms 1Giant Cell Tumor of Bone 1

Interventions

pembrolizumab 374Carboplatin 276Specimen Handling 265Nivolumab 252Magnetic Resonance Spectroscopy 244Cyclophosphamide 240Cisplatin 213Paclitaxel 206Radiotherapy 195Biopsy 171Gemcitabine 155Dexamethasone 148durvalumab 143atezolizumab 126Rituximab 120Doxorubicin 115Bevacizumab 114Lenalidomide 113Ipilimumab 111Radiation 109Docetaxel 103Pemetrexed 102Etoposide 101fludarabine 97venetoclax 95Fluorouracil 92Capecitabine 92Radiosurgery 90Prednisone 89Oxaliplatin 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Denosumab × 1 year × Clear all
NCT04549207 2026-04-07

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

Ottawa Hospital Research Institute

Phase 4 Active not recruiting
240 enrolled
Breast

Breast Neoplasms

NCT04067726 2026-03-31

TRIDENT

Washington University School of Medicine

Phase 2 Active not recruiting
210 enrolled
Breast

Breast Neoplasms

NCT02051218 2025-12-30

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Swiss Cancer Institute

Phase 3 Active not recruiting
1,380 enrolled
BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04586660 2025-10-01

Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

Amgen

Phase 4 Active not recruiting
36 enrolled

Giant Cell Tumor of Bone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡